SCHEMBL113705

SCHEMBL113705

CCOC(=O)c1cc(O)cc(C(=O)OCC)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.63
CA12 O43570 6/20 0.60
CA1 P00915 6/20 0.60
CA2 P00918 6/20 0.60
CA7 P43166 6/20 0.60
CA9 Q16790 6/20 0.60
CA14 Q9ULX7 6/20 0.60
NR1H2 P55055 1/20 0.58
NR1H3 Q13133 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.53
CYP3A4 P08684 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
POLB P06746 2/20 0.50
MAPK1 P28482 1/20 0.50
ESR1 P03372 1/20 0.50
ESR2 Q92731 1/20 0.50
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15892265 0.93 CYP1A2 (0.56) CYP1A2CA12CA1CA2CA7
SCHEMBL12161238 0.93 CYP1A2 (0.56) CYP1A2CA12CA1CA2CA7
SCHEMBL12161172 0.91 CYP1A2 (0.54) CYP1A2CA12CA1CA2CA7
SCHEMBL8922334 0.88 CYP1A2 (0.51) CYP1A2CA12CA1CA2CA7
SCHEMBL16477773 0.88 CA12 (0.51) CYP1A2CA12CA1CA2CA7
SCHEMBL12853621 0.86 CYP1A2 (0.49) CYP1A2CA12CA1CA2CA7
SCHEMBL862340 0.86 CYP1A2 (0.66) CYP1A2CA12CA1CA2CA7
SCHEMBL16472392 0.84 CYP1A2 (0.63) CYP1A2CA12CA1CA2CA7
SCHEMBL9128544 0.84 CYP1A2 (0.63) CYP1A2CA12CA1CA2CA7
SCHEMBL17594960 0.83 CYP1A2 (0.57) CYP1A2CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118317957-A Macrocyclic-containing compounds and radiolabeled complexes thereof as ligands in targeted radiotherapy applications 墨尔本大学 2024-07-09 CN disclosed
US-RE49918-E1 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2024-04-16 US disclosed
CN-114099676-B Synthetic method of self-assembly vesicle-like structure based on porphyrin molecule system 河南师范大学 2023-03-31 CN disclosed
CN-114099676-A Synthetic method of self-assembly vesicle-like structure based on porphyrin molecule system 河南师范大学 2022-03-01 CN disclosed
CN-107335061-B Cytotoxic benzodiazepine derivatives 伊缪诺金公司 2021-09-07 CN disclosed
CN-107531693-B 5 or 8-substituted imidazo [1, 5-a ] pyridines as indoleamine, tryptophan dioxygenase inhibitors 百济神州有限公司 2021-07-06 CN disclosed
US-20210171883-A1 ANTIVIRAL WIPER FUJIFILM CORPORATION (JP) 2021-06-10 US disclosed
EP-3280715-B1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE LTD (KY) 2020-11-25 EP disclosed
EP-3280715-B1 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES BEIGENE LTD (KY) 2020-11-25 EP disclosed
EP-3666289-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES ImmunoGen, Inc. (US) 2020-06-17 EP disclosed
US-6893716-B2 Non-covalent assembly of multilayer thin film supramolecular structures WORCESTER POLYTECHNIC INSTITUTE (US) 2005-05-17 US disclosed
US-20040110009-A1 Non-covalent assembly of multilayer thin film supramolecular structures WORCESTER POLYTECHNIC INSTITUTE 2004-06-10 US disclosed
EP-1379525-A2 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2004-01-14 EP disclosed
US-6660753-B2 For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease NPS PHARMACEUTICALS, INC. 2003-12-09 US disclosed
US-20030055085-A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2003-03-20 US disclosed
WO-2002068417-A3 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS SLASSI ABDELMALIK (CA) 2002-11-14 WO disclosed
WO-2002068417-A2 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2002-09-06 WO disclosed
US-6127390-A ANTITUMOR AGENTS INHIBITING FARNESYL-PROTEIN TRANSFERASE, FOR TREATING CANCER MERCK & CO., INC. (US) 2000-10-03 US disclosed
EP-1019391-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO. INC. (US) 2000-07-19 EP disclosed
WO-1999018096-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1999-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171883-A1 ANTIVIRAL WIPER CGAS, PRKX, PDE4C CYP1A2 3532/4885CA12 2396/4885CA1 2414/4885
US-20030055085-A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists GRM2, GRIN2A, GRM1 CYP1A2 4298/4885CA12 3922/4885CA1 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.